Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AB1 | P08238 | 20/20 | 0.72 |
| ▸ | HSP90AA1 | P07900 | 19/20 | 0.72 |
| ▸ | HSP90B1 | P14625 | 1/20 | 0.58 |
| ▸ | TRAP1 | Q12931 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4566975 | 0.86 | HSP90AA1 (0.59) | HSP90AB1HSP90AA1HSP90B1TRAP1 | |
| SCHEMBL421460 | 0.86 | HSP90AA1 (0.53) | HSP90AB1HSP90AA1HSP90B1TRAP1 | |
| SCHEMBL421085 | 0.85 | HSP90AA1 (0.52) | HSP90AB1HSP90AA1HSP90B1TRAP1 | |
| SCHEMBL4566974 | 0.85 | HSP90AA1 (0.58) | HSP90AB1HSP90AA1HSP90B1TRAP1 | |
| SCHEMBL4566973 | 0.85 | HSP90AA1 (0.58) | HSP90AB1HSP90AA1HSP90B1TRAP1 | |
| SCHEMBL421095 | 0.84 | HSP90AA1 (0.52) | HSP90AB1HSP90AA1HSP90B1TRAP1 | |
| SCHEMBL12046724 | 0.84 | HSP90AA1 (1.00) | HSP90AB1HSP90AA1HSP90B1TRAP1 | |
| SCHEMBL16604232 | 0.84 | HSP90AA1 (0.51) | HSP90AB1HSP90AA1HSP90B1TRAP1 | |
| SCHEMBL421109 | 0.84 | HSP90AB1 (0.78) | HSP90AB1HSP90AA1HSP90B1TRAP1 | |
| SCHEMBL421132 | 0.82 | HSP90AA1 (0.48) | HSP90AB1HSP90AA1HSP90B1TRAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 98 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180221345-A1 | COMBINATION THERAPY OF HSP90 INHIBITORS WITH PLATINUM-CONTAINING AGENTS | LSI FINANCING LLC, AS ADMINISTRATIVE AGENT | 2018-08-09 | — | — | US | disclosed |
| US-20180221345-A1 | COMBINATION THERAPY OF HSP90 INHIBITORS WITH PLATINUM-CONTAINING AGENTS | LSI FINANCING LLC, AS ADMINISTRATIVE AGENT | 2018-08-09 | — | — | US | disclosed |
| US-20170340652-A1 | COMBINATION THERAPY OF HSP90 INHIBITORY COMPOUNDS WITH CHK INHIBITORS | SYNTA PHARMACEUTICALS CORP. | 2017-11-30 | — | — | US | disclosed |
| US-20170340652-A1 | COMBINATION THERAPY OF HSP90 INHIBITORY COMPOUNDS WITH CHK INHIBITORS | SYNTA PHARMACEUTICALS CORP. | 2017-11-30 | — | — | US | disclosed |
| US-9439899-B2 | Cancer therapy using a combination of HSP90 inhibitors with topoisomerase I inhibitors | SYNTA PHARMACEUTICALS CORP. (US) | 2016-09-13 | — | — | US | disclosed |
| US-9439899-B2 | Cancer therapy using a combination of HSP90 inhibitors with topoisomerase I inhibitors | SYNTA PHARMACEUTICALS CORP. (US) | 2016-09-13 | — | — | US | disclosed |
| US-9402831-B2 | Combination therapy of HSP90 inhibitors with BRAF inhibitors | SYNTA PHARMACEUTICAL CORP. (US) | 2016-08-02 | — | — | US | disclosed |
| US-9402831-B2 | Combination therapy of HSP90 inhibitors with BRAF inhibitors | SYNTA PHARMACEUTICAL CORP. (US) | 2016-08-02 | — | — | US | disclosed |
| US-20160120849-A1 | CANCER THERAPY USING A COMBINATION OF A HSP90 INHIBITORY COMPOUNDS AND A EGFR INHIBITOR | SYNTA PHARMACEUTICALS CORP (US) | 2016-05-05 | — | — | US | disclosed |
| US-20160120849-A1 | CANCER THERAPY USING A COMBINATION OF A HSP90 INHIBITORY COMPOUNDS AND A EGFR INHIBITOR | SYNTA PHARMACEUTICALS CORP (US) | 2016-05-05 | — | — | US | disclosed |
| US-20100093717-A1 | TRIAZOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY | SYNTA PHARMACEUTICALS CORP | 2010-04-15 | — | — | US | disclosed |
| US-20100093717-A1 | TRIAZOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY | SYNTA PHARMACEUTICALS CORP | 2010-04-15 | — | — | US | disclosed |
| US-20080125587-A1 | Synthesis of triazole compounds that modulate HSP90 activity | SYNTA PHARMACEUTICALS CORP. | 2008-05-29 | — | — | US | disclosed |
| US-20080125587-A1 | Synthesis of triazole compounds that modulate HSP90 activity | SYNTA PHARMACEUTICALS CORP. | 2008-05-29 | — | — | US | disclosed |
| US-20080027047-A1 | Compounds that modulate HSP90 activity and methods for identifying same | SYNTA PHARMACEUTICALS CORP | 2008-01-31 | — | — | US | disclosed |
| US-20080027047-A1 | Compounds that modulate HSP90 activity and methods for identifying same | SYNTA PHARMACEUTICALS CORP | 2008-01-31 | — | — | US | disclosed |
| US-20080004276-A1 | Method for treating non-hodgkin's lymphoma | LSI FINANCING LLC, AS ADMINISTRATIVE AGENT | 2008-01-03 | — | — | US | disclosed |
| US-20080004276-A1 | Method for treating non-hodgkin's lymphoma | LSI FINANCING LLC, AS ADMINISTRATIVE AGENT | 2008-01-03 | — | — | US | disclosed |
| US-20080004266-A1 | Method for treating proliferative disorders associated with protooncogene products | LSI FINANCING LLC, AS ADMINISTRATIVE AGENT | 2008-01-03 | — | — | US | disclosed |
| US-20080004266-A1 | Method for treating proliferative disorders associated with protooncogene products | LSI FINANCING LLC, AS ADMINISTRATIVE AGENT | 2008-01-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180221345-A1 | COMBINATION THERAPY OF HSP90 INHIBITORS WITH PLATINUM-CONTAINING AGENTS | HSP90AB1, HSP90AA1, HSP90B1 | HSP90AB1 1/4885HSP90AA1 2/4885HSP90B1 3/4885 |
| US-20160120849-A1 | CANCER THERAPY USING A COMBINATION OF A HSP90 INHIBITORY COMPOUNDS AND A EGFR INHIBITOR | EGFR, HSP90AB1, HSP90AA1 | HSP90AB1 2/4885HSP90AA1 3/4885HSP90B1 4/4885 |
| US-20080125587-A1 | Synthesis of triazole compounds that modulate HSP90 activity | HSP90AB1, HSP90AA1, HSP90AB2P | HSP90AB1 1/4885HSP90AA1 2/4885HSP90B1 4/4885 |
| US-20170340652-A1 | COMBINATION THERAPY OF HSP90 INHIBITORY COMPOUNDS WITH CHK INHIBITORS | HSP90AB1, HSP90AA1, HSP90B1 | HSP90AB1 1/4885HSP90AA1 2/4885HSP90B1 3/4885 |
| US-20100093717-A1 | TRIAZOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY | HSP90AB1, HSP90AA1, HSP90AB2P | HSP90AB1 1/4885HSP90AA1 2/4885HSP90B1 4/4885 |
| US-20080004276-A1 | Method for treating non-hodgkin's lymphoma | HSP90AB1, HSP90AB2P, HSP90B1 | HSP90AB1 1/4885HSP90AA1 4/4885HSP90B1 3/4885 |
| US-20080027047-A1 | Compounds that modulate HSP90 activity and methods for identifying same | HSP90AB1, HSP90B1, CDC37 | HSP90AB1 1/4885HSP90AA1 4/4885HSP90B1 2/4885 |
| US-20080004266-A1 | Method for treating proliferative disorders associated with protooncogene products | HSP90AB1, HSP90AB2P, HSP90AA1 | HSP90AB1 1/4885HSP90AA1 3/4885HSP90B1 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.